Q-line Biotech Limited · NSE:QLINE
Q-line Biotech — H2 FY26 Earnings Presentation
29 slides from Q-line Biotech's earnings presentation
Slide 1: Investor Presentation – H2 & FY26
Investor Presentation – H2 & FY26 1
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), has been prepared by Q-line Biotech Limited (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form th
Slide 3: H2 & FY26 Highlights
H2 & FY26 fc Highlights
Slide 4: Management Commentary and FY27 Guidance
Management Commentary FY26 has been a transformative year for Q-Line Biotech Limited. The successful capitalization of our largest manufacturing facility in Lucknow marks a significant milestone in our journey and substantially strengthens our manufacturing capabilities. During the year, sales of ma
Slide 5: Key Developments Strengthening Long-Term Growth Drivers
Key Developments Strengthening Long-Term Growth Drivers Strong Recurring Revenue Base CDMO Opportunity Reagents grew 35% Y-o-Y and accounted for 69.8% of total Planning to commence CDMO operations through manufacturing revenue, supported by their consumable nature and strong of Selectra Pro M and Mi
Slide 6: Strong Growth with Significant Margin Expansion
Strong Growth with Significant Margin Expansion Revenue (Rs. Lakhs) Gross Profit (Rs. Lakhs) & Margin (%) EBITDA (Rs. Lakhs) & Margin (%) PAT (Rs. Lakhs) & Margin (%) CAGR : 23% CAGR : 30% CAGR : 43% CAGR : 20% 61% 29% 18% 17% 16% 34,174 54% 53% 31,314 52% 23% 18% 19% 20,763 9,805 18,274 20,
Slide 7: Consolidated Profit & Loss – H2 & FY26
Consolidated Profit & Loss – H2 & FY26 Particulars (Rs lakhs) H2FY26 H2FY25 Y-o-Y FY26 FY25 Y-o-Y Net Revenue from Operations 19,794 21,655 -9% 34,174 31,314 9% COGS 7,334 11,267 13,411 14,628 Gross Profit 12,459 10,388 20% 20,763 16,686 24% Gross Profit Margin (%) 62.9% 48.0% 1498 bps 60.8% 53.3% 7
Slide 8: Company Overview
te Q-lineBiotech Spreading Healthiness! Company {= Overview
Slide 9: Integrated IVD Platform with End-to-End Diagnostic Capabilities
Integrated IVD Platform with End-to-End Diagnostic Capabilities • Q-Line Biotech is engaged in the development, manufacturing, and marketing of diagnostic reagents, kits, Operational Metrics consumables, point-of-care (POC) devices, and diagnostic equipment. • The Company serves diagnostic laborator
Slide 10: 1. Reagents
1. Reagents • Essential Consumables used for In vitro testing (IVD) of human samples, Revenue (Rs. Lakhs) supporting disease prediction, prevention, diagnosis, monitoring, and overall 23,849 health status evaluation. 17,640 13,147 13,580 • Segment comprises of reagent kits, rapid cards, consumables
Slide 11: 2. Diagnostic Instruments
2. Diagnostic Instruments Diagnostic instruments Break up of Diagnostic Instrument Business PRODUCT PORTFOLIO SHOWCASE Diagnostic instruments, such as analyser’s and (Rs. in Lakhs) automated testing machines, are critical of performing tests with high accuracy and efficiency. With advancements in te
Slide 12: Diagnostic Instruments – Under Development
Diagnostic Instruments – Under Development A deep development roadmap expected to materially expand Q-Line's product portfolio and total addressable market, aligned with the Make in India initiative Clinical Haematology Coagulation Electrolyte Analyzer and an Analyzers Analyzer Analyzer Automated Sl
Slide 13: 3. Consumables and Service
3. Consumables and Service Consumables Services Variety of consumables are utilized in diagnostic tests and This includes the annual maintenance of the medical procedures, some of which are critical, including Macro Cuvettes equipment's that we sell to our customers with Balls, Lab Plastic Plates, L
Slide 14: Competitive Advantages Supporting Sustainable Growth
Competitive Advantages Supporting Sustainable Growth Integrated IVD International Make-in-India R&D Experienced Pan-India CDMO Platform Technology Tie-Ups Pioneer Division Leadership Distribution Reach Opportunity End-to-end Technology transfer One instrument 19 scientists and Chairman & MD Present
Slide 15: State-of-the-Art Manufacturing Facilities
State-of-the-Art Manufacturing Facilities Manufacturing Unit 1 Unit 2 Unit 3 Unit 4 Facility Location Delhi Lucknow Lucknow Lucknow Commencement May 2016 December 2023 December 2023 February 2026 Year Clinical Chemistry, Products Clinical Chemistry Clinical, Rapid, POC Reagents Molecular Reagents &
Slide 16: Diversified Geographic Presence
Diversified Geographic Presence Nationwide Reach. Growing Every Year. From government hospitals to reference labs, Q-Line products are embedded across India's diagnostic infrastructure, with export initiatives now extending to Africa, the Middle East and the Indian sub-continent Zonal Wise Revenue B
Slide 17: Experienced Leadership Team
Experienced Leadership Team SAURABH AYUSH YETHADKA SUBRAYA KULDEEP AJAY KUMAR MEENAL GARG GARG PRABHAKARA CHOWDHRY MAHANTY GUPTA Chairman & Non-Executive Director Whole Time Director Whole Time Director CEO CFO Managing Director Experience: Experience: Experience: Experience: Experience: Experience:
Slide 18: Roadmap for Scale, Diversification and Global Expansion
Roadmap for Scale, Diversification and Global Expansion Scale manufacturing — Make in India Deepen and widen market reach Grow manufacturing and production Target Key Account Sales through capacity aligned with the Government of Corporate Lab Chains in existing markets, India's "Make in India" initi
Slide 19: Industry Overview
te Q-lineBiotech Spreading Healthiness! Industry 4-2 Overview
Slide 20: Industry Landscape
Industry Landscape In-Vitro Diagnostics (IVD) serves as a critical component of the healthcare infrastructure, facilitating early disease detection and accurate diagnosis. Regulatory Post-Market Surveillance Supply Chain Process and Compliance Disruptions Manufacturers must obtain Manufacturers must
Slide 21: IVD Industry Landscape (1/3)
IVD Industry Landscape (1/3) In-Vitro Diagnostics (IVD) serves as a critical component of the healthcare infrastructure, facilitating early disease detection and accurate diagnosis. Rising burden of chronic diseases (diabetes, cardiovascular diseases, cancer) and infectious diseases (tuberculosis, d
Slide 22: Market Segmentation By Products - IVD Industry (2/3)
Market Segmentation By Products - IVD Industry (2/3) DIAGNOSTIC EQUIPMENT Includes Analyzers & Automated testing machines, critical for performing tests with high accuracy. REAGENTS & KITS Demand Driver: Advancements in technology and Holds the largest pie share, this 25% dominance is driven by the
Slide 23: Market Segmentation By End User Usability - IVD Industry (3/3)
Market Segmentation By End User Usability - IVD Industry (3/3) Hospital laboratories: Which constitute 38% of the market in CY25, underscoring their critical 30% role in diagnostic services for a wide range of medical conditions. 13% Clinical laboratories: Clinical laboratories follow closely, accou
Slide 24: Import Reliant India Self Sufficient India
Import Reliant India Self Sufficient India As India’s population grows and life expectancy increases, the demand for diagnostic solutions continues to rise. Government Initiatives: Production-Linked Incentive (PLI) Scheme: Incentives to manufacturers producing high-end diagnostic kits, reagents, and
Slide 25: Annual Financials
te Q-lineBiotech Spreading Healthiness! Annual [re Financials
Slide 26: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs lakhs) FY23* FY24* FY25 FY26 CAGR Net Revenue from Operations 18,274 20,365 31,314 34,174 23% COGS 8,847 9,302 14,628 13,411 Gross Profit 9,427 11,063 16,686 20,763 30% Gross Profit Margin (%) 51.6% 54.3% 53.3% 60.8% Employee Expenses 2,368 2,349
Slide 27: Consolidated Balance Sheet
Consolidated Balance Sheet Equity & Liabilities Assets Mar-23* Mar-24* Mar-25 Mar-26 (Rs lakhs) Mar-23* Mar-24* Mar-25 Mar-26 (Rs lakhs) Share Capital 158 158 158 1,628 Property, Plant & Equipment 2,280 5,992 7,364 14,158 and Intangible Assets Reserves & Surplus 12,579 16,024 18,838 22,992 Capital W
Slide 28: Initial Public Offering
Initial Public Offering IPO Details Shareholding Pattern (%) The company was successfully listed on NSE (SME platform) on 29th May 2026 Raised Rs. 214.48 crores through a fresh issuance of 62,53,000 equity shares 2% Utilization Proceeds: 10% ✓ Working Capital requirements ✓ Repayment of Borrowings ✓
Slide 29: Thank You
Thank You Q-line Biotech Limited Meenal Gupta - CFO meenal.gupta@poctservices.com 005 222 435570 Stellar IR Advisors Pvt Ltd Ankit Jain ankit@stellar-ir.com +91 22 62398024 29